<!-- page 1 -->

**==> picture [595 x 59] intentionally omitted <==**

**==> picture [595 x 60] intentionally omitted <==**

**==> picture [118 x 362] intentionally omitted <==**

Christopher Feinmann Technology Appraisal Project Manager NICE Peter House, Manchester. 

31 October 2006 

## **Single Technology Appraisal (STA) Fludarabine monotherapy for the first line treatment of chronic lymphocytic leukaemia Appraisal Consultation Document** 

Dear Christopher 

Thank you very much for inviting CHILDREN with LUEKAEMIA to comment on this STA. 

I have consulted extensively with our medical colleagues at Great Ormond Street hospital who treat childhood leukaemia.  Although they occasionally use Fludarabine for acute childhood leukaemia, they confirmed that children do not develop chronic lymphocytic leukaemia and therefore I do not feel it is appropriate or helpful for us to comment on this STA. 

**==> picture [118 x 363] intentionally omitted <==**

We would, however, be very interested in taking part in any future NICE consultation processes, particularly those relating to leukaemia in children. 

Thank you. 

CHILDREN with LEUKAEMIA 

